A Phase 1 Study of ETX-19477 in People With Advanced Solid Tumors

Full Title

Phase 1/2 Study of PARG inhibitor ETX-19477 in Patients with Advanced Solid Malignancies

Purpose

Researchers want to find the best dose of ETX-19477 to treat cancer. The people in this study have solid tumors that keep growing even after treatment.

ETX-19477 is designed to block a protein called PARG, which plays a role in cancer cell growth. By blocking PARG, ETX-19477 may help slow or stop the growth of your cancer. ETX-19477  is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a solid tumor that came back or keeps growing even after treatment.
• Have recovered from the serious side effects of prior anti-cancer treatments before taking ETX-19477.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be 18 or older.

Contact

For more information and to see if you can join this study, please call 646-888-4226.